Institutional Repository of Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959) | |
Dong,Di1,2,3; Zhang,Fan2,4; Zhong,Lian-Zhen1,3; Fang,Meng-Jie1,3; Huang,Cheng-Long2; Yao,Ji-Jin4; Sun,Ying2; Tian,Jie1,5; Ma,Jun2; Tang,Ling-Long2 | |
发表期刊 | BMC Medicine |
ISSN | 1741-7015 |
2019-10-23 | |
卷号 | 17期号:1页码:190 |
摘要 | AbstractBackgroundIn locoregionally advanced nasopharyngeal carcinoma (LANPC) patients, variance of tumor response to induction chemotherapy (ICT) was observed. We developed and validated a novel imaging biomarker to predict which patients will benefit most from additional ICT compared with chemoradiotherapy (CCRT) alone.MethodsAll patients, including retrospective training (n?=?254) and prospective randomized controlled validation cohorts (a substudy of NCT01245959, n?=?248), received ICT+CCRT or CCRT alone. Primary endpoint was failure-free survival (FFS). From the multi-parameter magnetic resonance images of the primary tumor at baseline, 819 quantitative 2D imaging features were extracted. Selected key features (according to their interaction effect between the two treatments) were combined into an Induction Chemotherapy Outcome Score (ICTOS) with a multivariable Cox proportional hazards model using modified covariate method. Kaplan-Meier curves and significance test for treatment interaction were used to evaluate ICTOS, in both cohorts.ResultsThree imaging features were selected and combined into ICTOS to predict treatment outcome for additional ICT. In the matched training cohort, patients with a high ICTOS had higher 3-year and 5-year FFS in ICT+CCRT than CCRT subgroup (69.3% vs. 45.6% for 3-year FFS, and 64.0% vs. 36.5% for 5-year FFS; HR?=?0.43, 95% CI?=?0.25–0.74, p?=?0.002), whereas patients with a low ICTOS had no significant difference in FFS between the subgroups (p?=?0.063), with a significant treatment interaction (pinteraction? |
关键词 | Individualized imaging biomarker Induction chemotherapy Survival benefit Treatment decision Locoregionally advanced nasopharyngeal cancer |
DOI | 10.1186/s12916-019-1422-6 |
收录类别 | SCI |
语种 | 英语 |
WOS记录号 | BMC:10.1186/s12916-019-1422-6 |
出版者 | BioMed Central |
七大方向——子方向分类 | 医学影像处理与分析 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.ia.ac.cn/handle/173211/26363 |
专题 | 中国科学院分子影像重点实验室 |
通讯作者 | Tian,Jie; Ma,Jun; Tang,Ling-Long |
作者单位 | 1.CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, No. 95 Zhongguancun East Road, Hai Dian District, Beijing 100190, People’s Republic of China. 2.Department of Radiation oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, People’s Republic of China. 3.School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing 100049, People’s Republic of China. 4.Department of Radiotherapy, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, People’s Republic of China. 5.Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine, Beihang University, Beijing 100191, People’s Republic of China. |
第一作者单位 | 中国科学院自动化研究所 |
通讯作者单位 | 中国科学院自动化研究所 |
推荐引用方式 GB/T 7714 | Dong,Di,Zhang,Fan,Zhong,Lian-Zhen,et al. Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959)[J]. BMC Medicine,2019,17(1):190. |
APA | Dong,Di.,Zhang,Fan.,Zhong,Lian-Zhen.,Fang,Meng-Jie.,Huang,Cheng-Long.,...&Tang,Ling-Long.(2019).Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959).BMC Medicine,17(1),190. |
MLA | Dong,Di,et al."Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959)".BMC Medicine 17.1(2019):190. |
条目包含的文件 | 下载所有文件 | |||||
文件名称/大小 | 文献类型 | 版本类型 | 开放类型 | 使用许可 | ||
2019_BMC Medicine_Do(3418KB) | 期刊论文 | 作者接受稿 | 开放获取 | CC BY-NC-SA | 浏览 下载 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论